These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 34073952)

  • 61. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
    Palmer SJ; Brady AJ; Ratcliffe AE
    Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differences in statin associated neuroprotection corresponds with either decreased production of IL-1β or TNF-α in an in vitro model of neuroinflammation-induced neurodegeneration.
    McFarland AJ; Davey AK; McDermott CM; Grant GD; Lewohl J; Anoopkumar-Dukie S
    Toxicol Appl Pharmacol; 2018 Apr; 344():56-73. PubMed ID: 29522792
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Metabolic interactions with statins].
    Molden E; Asberg A
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):189-93. PubMed ID: 11475198
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
    Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
    Yasuda N; Matzno S; Iwano C; Nishikata M; Matsuyama K
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):712-7. PubMed ID: 15927433
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes.
    Korhonova M; Doricakova A; Dvorak Z
    PLoS One; 2015; 10(9):e0137720. PubMed ID: 26366873
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
    Doggrell SA
    Rev Recent Clin Trials; 2006 May; 1(2):143-53. PubMed ID: 18473965
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Istvan ES
    Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Time-dependent effect of statins on platelet function in hypercholesterolaemia.
    Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Angori P; Auteri A; Bruni F
    Eur J Clin Invest; 2002 Dec; 32(12):901-8. PubMed ID: 12534449
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
    Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
    Russo E; Donato di Paola E; Gareri P; Siniscalchi A; Labate A; Gallelli L; Citraro R; De Sarro G
    Pharmacol Res; 2013 Apr; 70(1):1-12. PubMed ID: 23253428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.